Format

Send to

Choose Destination
See comment in PubMed Commons below
J Mol Med (Berl). 2009 Nov;87(11):1079-85. doi: 10.1007/s00109-009-0531-7. Epub 2009 Sep 17.

Cancer stem cells: controversies in multiple myeloma.

Author information

1
Division of Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA.

Abstract

Increasing data suggest that the initiation, relapse, and progression of human cancers are driven by specific cell populations within an individual tumor. However, inconsistencies have emerged in precisely defining phenotypic markers that can reliably identify these "cancer stem cells" in nearly every human malignancy studied to date. Multiple myeloma, one of the first tumors postulated to be driven by a rare population of cancer stem cells, is no exception. Similar to other diseases, controversy surrounds the exact phenotype and biology of multiple myeloma cells with the capacity for clonogenic growth. Here, we review the studies that have led to these controversies and discuss potential reasons for these disparate findings. Moreover, we speculate how these inconsistencies may be resolved through studies by integrating advancements in both myeloma and stem cell biology.

PMID:
19760278
PMCID:
PMC3015136
DOI:
10.1007/s00109-009-0531-7
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer Icon for PubMed Central
    Loading ...
    Support Center